Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award
Arcutis' ZORYVE cream 0.15% won Marie Claire's 2026 Best Prescription Skin Solution Award, the first prescription medication to receive the honor in a newly created category. The company notes ZORYVE is the number one prescribed branded topical therapy across eczema, plaque psoriasis, and seborrheic dermatitis combined, and this is its third major beauty-industry award.
Key figures
- Us atopic dermatitis patients
- over 26 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.